Search

Your search keyword '"Shaikh, Anjiya"' showing total 40 results
Start Over Author "Shaikh, Anjiya"
40 results on '"Shaikh, Anjiya"'

5. Global prevalence of MAFLD-related hepatocellular carcinoma: A systematic review and meta-analysis

Author

Crane, Harry, primary, Eslick, Guy D., additional, Gofton, Cameron, additional, Shaikh, Anjiya, additional, Cholankeril, George, additional, Cheah, Mark, additional, Zhong, Jian-Hong, additional, Svegliati-Baroni, Gianluca, additional, Vitale, Alessandro, additional, Kim, Beom Kyung, additional, Ahn, Sang Hoon, additional, Kim, Mi Na, additional, Strasser, Simone, additional, and George, Jacob, additional

Published
2024
Full Text
View/download PDF

10. Prognostic role of serum alpha-1 antitrypsin levels for waitlist mortality in patients with alcohol-associated liver disease

Author

Samuel, Ronald, primary, Ali, Basim, additional, Berger, Scott, additional, Bui, Richard, additional, Caskey, Kadon, additional, Goff, Cameron, additional, Hernandez, Norvin, additional, Kim, Seulgi, additional, Mathew, Christo, additional, Patel, Ankur, additional, Poche, Marguerite, additional, Pungwe, Prisca, additional, Shaikh, Anjiya, additional, Tran, Vinh, additional, Ward, Ryan, additional, Hernaez, Ruben, additional, Khaderi, Saira, additional, Lee, Tzu-hao, additional, Kanwal, Fasiha, additional, and Cholankeril, George, additional

Published
2023
Full Text
View/download PDF

11. Survival following liver transplantation for hepatocellular carcinoma after implementation of MMaT-3 policy

Author

Shaikh, Anjiya, primary, Lee, Tzu-Hao, additional, Rich, Nicole E., additional, Benhammou, Jihane N., additional, Lymberopoulos, Peter, additional, Agopian, Vatche G., additional, Kim, Donghee, additional, Ahmed, Aijaz, additional, Hernaez, Ruben, additional, Berg, Carl L., additional, Goss, John, additional, Rana, Abbas, additional, Kanwal, Fasiha, additional, and Cholankeril, George, additional

Published
2023
Full Text
View/download PDF

12. Depression in nonalcoholic fatty liver disease and all‐cause/cause‐specific mortality.

Author

Kim, Donghee, Manikat, Richie, Shaikh, Anjiya, Cholankeril, George, and Ahmed, Aijaz

Subjects
NON-alcoholic fatty liver disease, HEALTH & Nutrition Examination Survey, FATTY liver
Abstract

Background: Depression has been associated with nonalcoholic fatty liver disease (NAFLD). Data addressing the impact of depression on NAFLD‐related mortality are evolving. We aim to study the association of depression in NAFLD and all‐cause/cause‐specific mortality in the United States. Methods: A total of 11,877 individuals with NAFLD in the 2007–2016 National Health and Nutrition Examination Survey with the availability of linked mortality through 2019 were analysed. NAFLD was defined by utilizing the hepatic steatosis index in the absence of known causes of chronic liver disease. Depression and functional impairment due to depression were assessed using the Patient Health Questionnaire. Results: During the median follow‐up of 7.6 years, individuals with depression among individuals with NAFLD had a 35% higher all‐cause mortality than those without depression (hazard ratio [HR]: 1.35, 95% confidence interval [CI]: 1.03–1.75) after adjusting for demographic, lifestyle and clinical risk factors. NAFLD with functional impairment due to depression had a 62% higher all‐cause mortality than NAFLD without functional impairment (HR: 1.62, 95% CI: 1.10–2.39). Depression in NAFLD was associated with an approximately 50% increase in the risk for cardiovascular mortality, with a 2‐fold higher cardiovascular mortality in those with functional impairment compared to those without (HR: 2.07, 95% CI: 1.30–3.30). However, there was no significant difference in cancer‐ and accident‐related mortalities in NAFLD with or without depression. Conclusions: Depression among individuals with NAFLD was associated with a higher risk for all‐cause and cardiovascular mortality in the United States. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

15. Reduction in Racial and Ethnic Disparity in Survival Following Liver Transplant for Hepatocellular Carcinoma in the Direct-acting Antiviral Era

Author

Shaikh, Anjiya, primary, Goli, Karthik, additional, Lee, Tzu-Hao, additional, Rich, Nicole E., additional, Benhammou, Jihane N., additional, Keeling, Stephanie, additional, Kim, Donghee, additional, Ahmed, Aijaz, additional, Goss, John, additional, Rana, Abbas, additional, Singal, Amit G., additional, Kanwal, Fasiha, additional, and Cholankeril, George, additional

Published
2022
Full Text
View/download PDF

16. Improved Survival After Liver Transplantation for Patients With Human Immunodeficiency Virus (HIV) and HIV/Hepatitis C Virus Coinfection in the Integrase Strand Transfer Inhibitor and Direct-Acting Antiviral Eras

Author

Jacob, Jake Sheraj, primary, Shaikh, Anjiya, additional, Goli, Karthik, additional, Rich, Nicole E, additional, Benhammou, Jihane N, additional, Ahmed, Aijaz, additional, Kim, Donghee, additional, Rana, Abbas, additional, Goss, John A, additional, Naggie, Susanna, additional, Lee, Tzu-Hao, additional, Kanwal, Fasiha, additional, and Cholankeril, George, additional

Published
2022
Full Text
View/download PDF

20. Contemporary Changes in Etiology for Hepatocellular Carcinoma in Liver Transplantation

Author

Goff, Cameron, primary, Shaikh, Anjiya, additional, Goli, Karthik, additional, El-Serag, Hashem B., additional, Kanwal, Fasiha, additional, Cholankeril, George, additional, Rana, Abbas, additional, Aloor, Faud Z., additional, Cholankeril, Rosann, additional, Rich, Nicole E., additional, Benhammou, Jihane N., additional, Kim, Donghee, additional, Ahmed, Aijaz, additional, and Goss, John, additional

Published
2022
Full Text
View/download PDF

24. EP1218: REDUCTION IN RACIAL/ETHNIC DISPARITIES FOR LIVER TRANSPLANTATION IN AFRICAN AMERICANS WITH HCC DURING THE DAA ERA

Author

Shaikh, Anjiya T., primary, Goli, Karthik, additional, Lymberopoulos, Peter, additional, Allam, Anthony Kaspa R., additional, Benhammou, Jihane N., additional, Lee, Tzu-Hao, additional, Rich, Nicole E., additional, Goss, John A., additional, Ahmed, Aijaz, additional, Rana, Abbas, additional, Kanwal, Fasiha, additional, and Cholankeril, George T., additional

Published
2022
Full Text
View/download PDF

27. EP1214: EARLY LIVING DONOR LIVER TRANSPLANT PROVIDES HIGHEST OVERALL SURVIVAL BENEFIT IN LOW MELD PATIENTS AWAITING LIVER TRANSPLANTATION

Author

Allam, Anthony Kaspa R., primary, Malik, Tahir H., additional, Patel, Ankur, additional, Shaikh, Anjiya, additional, Benhammou, Jihane N., additional, Rich, Nicole E., additional, Goss, John A., additional, Kim, Donghee, additional, Ahmed, Aijaz, additional, Rana, Abbas, additional, Lee, Tzu-Hao, additional, Kanwal, Fasiha, additional, and Cholankeril, George T., additional

Published
2022
Full Text
View/download PDF

29. Experience of Telemedicine in Gastroenterology Out-Patient Practice During the COVID-19 Pandemic: Experiences from a Tertiary-Care Hospital in a Developing Country

Author

Shaikh,Anjiya, Khan,Maria, Ismail,Faisal Waseem, Shaikh,Anjiya, Khan,Maria, and Ismail,Faisal Waseem

Abstract

Anjiya Shaikh,1,* Maria Khan,2,* Faisal Waseem Ismail3 1Department of Medicine, University of Connecticut School of Medicine, Farmington, CT, USA; 2Department of Medicine, Aga Khan University, Karachi, Sindh, Pakistan; 3Section of Gastroenterology, Department of Medicine, Aga Khan University, Karachi, Sindh, Pakistan*These authors contributed equally to this workCorrespondence: Faisal Waseem Ismail, Department of Medicine, Aga Khan University, Karachi, Sindh, Pakistan, Tel +92-3009214175, Email faisal.ismail@aku.eduObjective: Telemedicine is being widely implemented in the COVID-19 pandemic to avoid infection risk. However, its effectiveness has not been evaluated, especially in developing countries, where it is invaluable for healthcare access. This study assesses physicians’ and patients’ perspectives of the usefulness and challenges of telemedicine in the gastroenterology department to identify its pitfalls.Methods: A cross-sectional telephonic survey was conducted on patients presenting to the gastroenterology department at a tertiary care hospital in Pakistan. An online survey was sent to physicians in the department.Results: A total of 160 patients participated, with a mean age 49.8 years, and 42.8% (n=68) males. There were 23.8% (n=38) initial visits and 76.3% (n=122) follow-ups. More than 85% of patients agreed telemedicine saved cost and time, 46.5% (n=74) said it improved healthcare access, and 76.3% (n=122) wanted to use it again. More than 80% were satisfied with the physician-patient interaction. Of the 7 physicians who participated, most felt telemedicine was inadequately facilitated, but felt comfortable with technology. Most felt it did not negatively affect healthcare, but thought it was complex for patients and that lack of physical interaction is a limitation. Nearly half were in favor of continuing its use after the pandemic.Conclusion: Telemedicine is an effective alternative to in-person visits. Patients find it conv

Published
2022

30. Improved Survival After Liver Transplantation for Patients With Human Immunodeficiency Virus (HIV) and HIV/Hepatitis C Virus Coinfection in the Integrase Strand Transfer Inhibitor and Direct-Acting Antiviral Eras.

Author

Jacob, Jake Sheraj, Shaikh, Anjiya, Goli, Karthik, Rich, Nicole E, Benhammou, Jihane N, Ahmed, Aijaz, Kim, Donghee, Rana, Abbas, Goss, John A, Naggie, Susanna, Lee, Tzu-Hao, Kanwal, Fasiha, and Cholankeril, George

Subjects
*HIV infection prognosis, *HIV infections, *HIV integrase inhibitors, *CONFIDENCE intervals, *AGE distribution, *HEPATITIS C, *ANTIVIRAL agents, *RETROSPECTIVE studies, *TREATMENT effectiveness, *MIXED infections, *DESCRIPTIVE statistics, *RESEARCH funding, *KAPLAN-Meier estimator, *LIVER transplantation, *SECONDARY analysis
Abstract

Background People with human immunodeficiency virus (HIV) with and without hepatitis C virus (HCV) coinfection had poor outcomes after liver transplant (LT). Integrase strand transfer inhibitors (INSTIs) and direct-acting antivirals (DAAs) have changed the treatment landscape for HIV and HCV, respectively, but their impact on LT outcomes remains unclear. Methods This retrospective analysis of adults with HIV monoinfection (n = 246) and HIV/HCV coinfection (n = 286) who received LT compared mortality in patients with HIV who received LT before versus after approval of INSTIs and in patients with HIV/HCV coinfection who received LT before versus after approval of DAAs. In secondary analysis, we compared the outcomes in the different eras with those of propensity score–matched control cohorts of LT recipients without HIV or HCV infection. Results LT recipients with HIV monoinfection did not experience a significant improvement in survival between the pre-INSTI and INSTI recipients with HIV (adjusted hazard ratio [aHR], 0.70 [95% confidence interval {CI},.36–1.34]). However, recipients with HIV/HCV coinfection in the DAA era had a 47% reduction (aHR, 0.53 [95% CI,.31–9.2] in 1-year mortality compared with coinfected recipients in the pre-DAA era. Compared to recipients without HIV or HCV, HIV-monoinfected recipients had higher mortality during the pre-INSTI era, but survival was comparable between groups during the INSTI era. HIV/HCV-coinfected recipients also experienced comparable survival during the DAA era compared to recipients without HCV or HIV. Conclusions Post-LT survival for people with HIV monoinfection and HIV/HCV coinfection has improved with the introduction of INSTI and DAA therapy, suggesting that LT has become safer in these populations. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

33. FRI-448 - Prognostic role of serum alpha-1 antitrypsin levels for waitlist mortality in patients with alcohol-associated liver disease

Author

Samuel, Ronald, Ali, Basim, Berger, Scott, Bui, Richard, Caskey, Kadon, Goff, Cameron, Hernandez, Norvin, Kim, Seulgi, Mathew, Christo, Patel, Ankur, Poche, Marguerite, Pungwe, Prisca, Shaikh, Anjiya, Tran, Vinh, Ward, Ryan, Hernaez, Ruben, Khaderi, Saira, Lee, Tzu-hao, Kanwal, Fasiha, and Cholankeril, George

Published
2023
Full Text
View/download PDF

38. Linezolid use and drug-induced liver injury.

Author

Shaikh, Anjiya and McHugh, Jack

Abstract

Linezolid is a frequently prescribed antibiotic for chronic infection suppression, such as in prosthetic joint infections. While well tolerated, its prolonged use can increase the risk of rare and serious side effects. We present a case of linezolid toxicity presenting with a constellation of adverse effects including bone marrow suppression, lactic acidosis, and drug-induced liver injury. Our case highlights the increased risk of acute multiorgan failure in patients using the antibiotic for extended durations, notably those with preexisting comorbidities. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

39. Long-term outcomes and trends in liver transplantation for hereditary hemochromatosis in the United States.

Author

Lymberopoulos P, Prakash S, Shaikh A, Bhatnagar A, Allam AK, Goli K, Goss JA, Kanwal F, Rana A, Kowdley KV, Jalal P, and George Cholankeril

Subjects
Adult, Humans, United States epidemiology, Proportional Hazards Models, Retrospective Studies, Hemochromatosis surgery, Hemochromatosis etiology, Liver Transplantation adverse effects, Liver Diseases surgery, Liver Diseases etiology
Abstract

There have been conflicting data regarding liver transplantation (LT) outcomes for hereditary hemochromatosis (HH), with no recent data on LT outcomes in patients with HH in the past decade. Using the United Network for Organ Sharing registry, we evaluated waitlist and post-LT survival in all adult patients listed for HH without concomitant liver disease from 2003 to 2019. Post-LT survival for HH was compared with a propensity-matched (recipient and donor factors) cohort of recipients with chronic liver disease (CLD). From 2003 to 2019, 862 patients with HH were listed for LT, of which 55.6% ( n = 479) patients underwent LT. The 1- and 5-year post-LT survival rates in patients with HH were 88.7% (95% confidence interval [CI], 85.4%-91.4%) and 77.5% (95% CI, 72.8%-81.4%), respectively, and were comparable with those in the propensity-matched CLD cohort ( p value = 0.96). Post-LT survival for HH was lower than for Wilson's disease, another hereditary metabolic liver disease with similar LT volume ( n = 365). Predictors for long-term (5-year) post-LT mortality included presence of portal vein thrombosis (hazard ratio [HR], 1.96; 95% CI, 1.07-3.58), obesity measurements greater than Class II (HR, 1.98; 95% CI, 1.16-3.39), and Karnofsky performance status (HR, 0.98; 95% CI, 0.97-0.99) at the time of LT. The leading cause of post-LT death ( n = 145) was malignancy (25.5%), whereas cardiac disease was the cause in less than 10% of recipients. In conclusion, short- and long-term survival rates for HH are excellent and comparable with those of other LT recipients. Improving extrahepatic metabolic factors and functional status in patients with HH prior to LT may improve outcomes., (Copyright © 2022 American Association for the Study of Liver Diseases.)

Published
2023
Full Text
View/download PDF

40. Linezolid use and drug-induced liver injury.

Author

Shaikh A and McHugh J

Abstract

Linezolid is a frequently prescribed antibiotic for chronic infection suppression, such as in prosthetic joint infections. While well tolerated, its prolonged use can increase the risk of rare and serious side effects. We present a case of linezolid toxicity presenting with a constellation of adverse effects including bone marrow suppression, lactic acidosis, and drug-induced liver injury. Our case highlights the increased risk of acute multiorgan failure in patients using the antibiotic for extended durations, notably those with preexisting comorbidities., (Copyright © 2020 Baylor University Medical Center.)

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results